309 related articles for article (PubMed ID: 38629293)
1. Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.
Li S; Zhang H; Chen T; Zhang X; Shang G
Cancer Med; 2024 Apr; 13(8):e7201. PubMed ID: 38629293
[TBL] [Abstract][Full Text] [Related]
2. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
4. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
5. ROS1-rearranged Non-small Cell Lung Cancer.
Giustini NP; Bazhenova L
Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract][Full Text] [Related]
9. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
10. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
11. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
12. TRUST-II: a global phase II study of taletrectinib in
Nagasaka M; Ohe Y; Zhou C; Choi CM; Yang N; Liu G; Felip E; Pérol M; Besse B; Nieva J; Raez L; Pennell NA; Dimou A; Marinis F; Ciardiello F; Seto T; Hu Z; Pan M; Wang W; Li S; Ou SI
Future Oncol; 2023 Jan; 19(2):123-135. PubMed ID: 36877099
[TBL] [Abstract][Full Text] [Related]
13. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.
Ou SI; Zhu VW
Lung Cancer; 2019 Apr; 130():201-207. PubMed ID: 30885345
[TBL] [Abstract][Full Text] [Related]
14. Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors.
Iyer SR; Nusser K; Jones K; Shinde P; Keddy C; Beach CZ; Aguero E; Force J; Shinde U; Davare MA
EMBO Mol Med; 2023 Oct; 15(10):e17367. PubMed ID: 37587872
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
17. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
18. An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).
Liu M; Dai J; Wei M; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Jun; 32(6):713-729. PubMed ID: 35343863
[TBL] [Abstract][Full Text] [Related]
19. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
Nagasaka M; Zhang SS; Baca Y; Xiu J; Nieva J; Vanderwalde A; Swensen JJ; Spetzler D; Korn WM; Raez LE; Liu SV; Ou SI
BMC Cancer; 2023 Oct; 23(1):1000. PubMed ID: 37853341
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
